Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ImmunoGen, Inc.    IMGN

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

ImmunoGen, Inc. : Initiates Phase I Trial in Non-Hodgkin's Lymphoma with Its Novel IMGN529 Anticancer Compound

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/17/2012 | 12:20pm CET

- First of Two Unique ImmunoGen Product Candidates Expected to Enter Clinic in 2012 -

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops anticancer therapeutics using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced the start of clinical testing with its IMGN529 product candidate. The Phase I trial initiated evaluates the safety, tolerability, pharmacokinetic profile and anticancer activity of escalating doses of IMGN529 in patients with non-Hodgkin's lymphoma (NHL) to establish the dose for future clinical trials.

Today NHL is frequently treated with the anticancer antibody, rituximab (Rituxan®), and/or with chemotherapy. The novel agent IMGN529, a TAP compound, contains a B-cell-targeting antibody that has demonstrated marked anticancer activity in preclinical testing.1 Attached to this antibody is a potent ImmunoGen cell-killing agent, DM1. The antibody serves: (1) to kill the cancer cells through multiple antibody-mediated mechanisms; and (2) to deliver the DM1 specifically to the cancer cells for additional, targeted anticancer potency.

"The Phase I trial now underway, together with our market research, is expected to provide the information needed to define a clear development path for IMGN529 in NHL," commented James O'Leary, MD, Vice President and Chief Medical Officer. "With its unique profile, we believe IMGN529 has the potential to be an important new therapy for the treatment of key B-cell malignancies."

About the Phase I Trial Initiated

This multi-center, first-in-human Phase I trial is expected to enroll approximately 55 patients with relapsed or relapsed/refractory, CD37-expressing NHL. Patients with follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, or marginal zone lymphoma - the more common types of NHL - are eligible for enrollment.

About IMGN529

ImmunoGen created IMGN529 for the treatment of B-cell malignancies that express its CD37 target. The prevalence of CD37 on malignant cells is similar to that of CD20, the target for rituximab: it is expressed widely on key NHL subtypes - including follicular lymphoma, diffuse large B-cell lymphoma, marginal zone lymphoma and mantle cell lymphoma - and also on chronic lymphocytic leukemia (CLL).1

IMGN529 contains a CD37-targeting ImmunoGen antibody that, in vitro, has been found to kill cancer cells through multiple mechanisms of action including pro-apoptotic activity, complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC).1,2 The attached DM1 kills cancer cells through a different mechanism - disruption of a key step that occurs during cell division.

About Non-Hodgkin's lymphoma

NHL comprises a diverse group of cancers that all derive from defects in cellular production of lymphocytes, a type of white blood cell. As the name suggests, NHL includes all lymphomas except Hodgkin's lymphoma. Approximately 85% of cases of NHL are B-cell lymphomas. It is estimated that, in the US, approximately 56,000 people are diagnosed with B-cell NHL each year and 16,000 die from the disease.3

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using the Company's expertise in tumor biology, monoclonal antibodies, potent cancer-cell killing agents and engineered linkers. The Company's TAP technology uses monoclonal antibodies to deliver one of ImmunoGen's proprietary cancer-cell killing agents specifically to tumor cells. There are now numerous TAP compounds in clinical development with a wealth of clinical data reported. ImmunoGen's collaborative partners include Amgen, Bayer HealthCare, Biotest, Lilly, Novartis, Roche, and Sanofi. The most advanced compound using ImmunoGen's TAP technology, trastuzumab emtansine (T-DM1), is in Phase III testing through the Company's collaboration with Genentech, a member of the Roche Group. More information about ImmunoGen can be found at www.immunogen.com.

1Mayo M. et al., AACR 2011, abstract #4581.
2Deckert J. et al., AACR 2011, abstract #4565.
3American Cancer Society, What is non-Hodgkin's Lymphoma.

Rituxan® is a registered trademark of Biogen Idec Inc.

This press release includes forward-looking statements. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. It should be noted that there are risks and uncertainties related to the development of novel anticancer products, including IMGN529, including risks related to preclinical and clinical studies, their timings and results. A review of these risks can be found in ImmunoGen's Annual Report on Form 10-K for the fiscal year ended June 30, 2011 and other reports filed with the Securities and Exchange Commission.

For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations and Corporate Communications
[email protected]
or
For Media:
The Yates Network
Kathryn Morris, 845-635-9828


© Business Wire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on IMMUNOGEN, INC.
11/17 IMMUNOGEN : Biotechnology and Oncology Markets Have Positive Projections
11/09 IMMUNOGEN : to Present New Data on Novel Antibody-Drug Conjugates at 59th ASH An..
11/09 IMMUNOGEN : Management's Discussion and Analysis of Financial Condition and Resu..
11/07 IMMUNOGEN : Announces Webcasts of Presentations at Upcoming Conferences
11/03 IMMUNOGEN, INC. (NASDAQ : IMGN) reported earnings of ($0.61) per share missing W..
11/03 IMMUNOGEN : reports 3Q loss
11/03 IMMUNOGEN INC : Results of Operations and Financial Condition, Financial Stateme..
11/03 IMMUNOGEN : Reports Recent Progress and Third Quarter 2017 Operating Results
11/02 IMMUNOGEN : Patent Issued for Methods for the Acylation of Maytansinol (USPTO 97..
11/01 IMMUNOGEN : to Present New Data on Novel Antibody-Drug Conjugates at 59th ASH An..
More news
News from SeekingAlpha
11/16 ImmunoGen (IMGN) Presents At Jefferies 2017 London Healthcare Conference - Sl..
11/15 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
11/03 Immunogen's (IMGN) CEO Mark Enyedy on Q3 2017 Results - Earnings Call Transcr..
11/03 PREMARKET LOSERS AS OF 9 : 05 am
11/03 ImmunoGen Q3 revenues up 10%; updates guidance
Financials ($)
Sales 2016 69,2 M
EBIT 2016 -113 M
Net income 2016 -131 M
Debt 2016 19,2 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales 2016 14,0x
Capi. / Sales 2017 8,15x
Capitalization 952 M
Chart IMMUNOGEN, INC.
Duration : Period :
ImmunoGen, Inc. Technical Analysis Chart | IMGN | US45253H1014 | 4-Traders
Technical analysis trends IMMUNOGEN, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 9,50 $
Spread / Average Target 54%
EPS Revisions
Managers
NameTitle
Mark J. Enyedy President, Chief Executive Officer & Director
Stephen C. McCluski Chairman
David B. Johnston Chief Financial Officer & Executive Vice President
Richard J. Gregory Chief Scientific Officer & Executive VP
Anna Berkenblit Chief Medical Officer & Vice President
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNOGEN, INC.201.47%952
CELLTRION, INC.--.--%24 558
INCYTE CORPORATION5.19%22 258
IQVIA HOLDINGS INC37.36%22 074
LONZA GROUP59.15%19 560
ALNYLAM PHARMACEUTICALS, INC.240.57%12 538